Key Insights

Highlights

Treatment Research

3 treatments under study, led by Psma11

Research Leaders

14 sponsors active, led by Erasmus Medical Center

Related Conditions

Often studied with 5 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 1 (1)

Trial Status

Active Not Recruiting2

Clinical Trials (2)

Showing 2 of 2 trials
NCT05917860Phase 1Active Not Recruiting

Neoadjuvant ADT With TULSA in the Treatment of Intermediate Risk Prostate Cancer

NCT07455097Active Not RecruitingPrimary

COMBINED PSMA-PET/CT AND MRI STAGING IN INTERMEDIATE AND HIGH-RISK PATIENTS PROSTATA-CANCER (COMBINE-P)

Showing all 2 trials

Research Network

Common Treatments

  • Psma111
  • Degarelix1
  • Mriguided Transurethral Ultrasound Ablation Tulsa1

Active Sponsors

  • Erasmus Medical Center1
  • Fortis Hospital, India1
  • KU Leuven1
  • Heinrich-Heine University, Duesseldorf1
  • European Association of Urology Research Foundation1

Top Investigators

Related Conditions

  • Intermediate Risk Prostate Cancer1
  • Prostate Cancer1
  • Highrisk Prostate Cancer1
  • Localized Prostate Carcinoma1
  • Castrationnaive Prostate Cancer1

Activity Timeline